Our Company

Enabling Life-Changing Therapies with Excellence and Commitment.

Tigermed (300347.SZ/3347.HK) is a leading full-service global CRO for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, we are devoted to moving our customers through their development journey efficiently and cost-effectively.

Global Employees
9,500+
Global Customers
2,600+
Global Offices and Locations
180+
China Innovative Drugs Supported
64

A Full Service CRO for Healthcare Innovation

Whether you are developing a small molecule or biologic, a vaccine or medical device, we have tailored solutions to move your research forward.

Small Molecule
Biologics
Cell & Gene Therapy
Medical Device
Rare Disease
Vaccine

A Global Presence

Tigermed currently represents a worldwide network of more than 100 subsidiaries and 180 offices and sites, with over 9,500 employees across 54 countries in Asia Pacific, Europe, North & South America and Africa.

Advance Human Health through Delivery Excellence

Watch Our Corporate Video

Learn more about Our History

Key Milestones of Corporate History

Tigermed

2004

MacroStat

2005

Jiaxing Tigermed

2010

Hangzhou SIMO

Tigermed Hong Kong

2011

IPO in Shenzhen Stock Exchange (300347.SZ)

Fantastic Imaging

2012

Talent

IntelliPV

Tigermed Australia

Tigermed Taiwan

Bioquick

2013

Frontage Lab

Canny Consulting

Clinflash

TigerYeah Capital

2014

DreamCIS

Beijing BDN

2015

Teddy Laboratory

Tigermed India

2016

Tigermed-Jyton

Tigermed Switzerland

2017

OperaCRO

2018

Tigermed America

BRI Pharmaceutical & RMI Laboratories

Frontage IPO in HKSE (1521.HK)

Wuxi Tigermed

Yaxincheng

2019

Listed in HKEX (3347.HK)

DreamCIS IPO in Korea

Mosim

Joint-venture Tigerise

2020

Hainan Tigermed

Global expansion to Latin America, Africa and Middle East

Support of CanSino COVID-19 vaccine

2021

Customer Recognition is Our

Driving Force

From our Customers

Best CRO Partnership Award | Merck

Global Supplier Award | Lilly

Outstanding Service Award | Merck

Best Startup Award | Hua Medicine

Best Strategic Collaboration Partner | Sinocelltech

Excellent Teamwork Award | Hutchison

Best Execution Partner Award | Betta Pharma

Best Strategic Partnership Award | Genorbio

Best SMO Company | Cancer Hospital of Peking University

From the Industry

2022 AAA in CNI ESG Rating by Shenzhen Stock Exchange

2021 FORTUNE The Future 50 Companies

2021 Frost & Sullivan “China Competitive Strategy Leadership”

2020 Frost & Sullivan "China CRO Customer Value Leadership"

2020 China Biopharmaceutical lndustry "Best Clinical CRO"

2019 Forbes Asia's 200 Best Under A Billion Companies

2019 Top 10 Most Valuable Pharma Company to lnvest

Recognized as 2019 Top 500 listed companies in China